An evaluation of the anti-hyperalgesic effects of cannabidiolic acid-methyl ester in a preclinical model of peripheral neuropathic pain.

ABSTRACT:

Background and purpose

Chronic neuropathic pain (NEP) is associated with growing therapeutic cannabis use. To promote quality of life without psychotropic effects, cannabinoids other than Δ9-tetrahydrocannabidiol, including cannabidiol and its precursor cannabidiolic acid (CBDA), are being evaluated. Due to its instability, CBDA has been understudied, particularly as an anti-nociceptive agent. Adding a methyl ester group (CBDA-ME) significantly enhances its stability, facilitating analyses of its analgesic effects in vivo. This study examines early treatment efficacy of CBDA-ME in a rat model of peripherally induced NEP and evaluates sex as a biological variable.

Experimental approach

After 14 consecutive days of intraperitoneal CBDA-ME administration at 0.01, 0.1 and 1 μg·k

SUBMITTER: Zhu YF 

PROVIDER: S-EPMC7236066 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature